Press releases

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ --...

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ --...

MARLBOROUGH, Mass., Oct. 11, 2023 -- Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha™...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday,...

Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass., Sept. 19, 2023 /PRNewswire/ -- Boston...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific...

Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between...

Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine...

First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems MARLBOROUGH, Mass., Aug. 8, 2023 /PRNewswire/ -- Boston...

Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational1 basis...